Ocular Therapeutix Inc. (OCUL)

4.27
NASDAQ : Health Technology
Prev Close 4.30
Day Low/High 4.23 / 4.34
52 Wk Low/High 2.35 / 7.31
Avg Volume 735.70K
Exchange NASDAQ
Shares Outstanding 47.20M
Market Cap 202.94M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
OCULAR THERAPEUTIX INVESTOR ALERT: Legal Investigation Continues After FDA Denies Dextenza New Drug Application

OCULAR THERAPEUTIX INVESTOR ALERT: Legal Investigation Continues After FDA Denies Dextenza New Drug Application

Girard Gibbs LLP is investigating potential claims on behalf of investors of Ocular Therapeutix, Inc.

OCULAR THERAPEUTIX INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Ocular Therapeutix, Inc. To Contact The Firm

OCULAR THERAPEUTIX INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Ocular Therapeutix, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Ocular Therapeutix, Inc.

Ocular Therapeutix™ Receives Complete Response Letter From FDA For DEXTENZA™ NDA

Ocular Therapeutix™ Receives Complete Response Letter From FDA For DEXTENZA™ NDA

Ocular Therapeutix TM, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, announced today that it...

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Ocular Therapeutix, Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Ocular Therapeutix, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces the filing of a securities class action lawsuit against Ocular Therapeutix, Inc.

Ocular Therapeutix™ Submits Amendment To Potentially Extend Review For DEXTENZA™ New Drug Application (NDA)

Ocular Therapeutix™ Submits Amendment To Potentially Extend Review For DEXTENZA™ New Drug Application (NDA)

Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, announced today that...

OCULAR THERAPEUTIX INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Ocular Therapeutix, Inc. To Contact The Firm

OCULAR THERAPEUTIX INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Ocular Therapeutix, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Ocular Therapeutix, Inc.

These Stocks Are Changing Directions

These Stocks Are Changing Directions

Bullish and bearish reversals in the market.

OCULAR THERAPEUTIX INVESTOR ALERT: Legal Investigation For Potential Securities Law Violations

OCULAR THERAPEUTIX INVESTOR ALERT: Legal Investigation For Potential Securities Law Violations

Girard Gibbs LLP is investigating potential claims on behalf of investors of Ocular Therapeutix, Inc.

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Ocular Therapeutix, Inc. - OCUL

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Ocular Therapeutix, Inc. - OCUL

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Ocular Therapeutix, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Ocular Therapeutix, Inc. - OCUL

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Ocular Therapeutix, Inc. - OCUL

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Ocular Therapeutix, Inc.

3 Small Biotechs on the FDA Summer Calendar

3 Small Biotechs on the FDA Summer Calendar

Dynavax Technologies, Ocular Therapeutix and Neos Therapeutics have big drug approval dates ahead.

Ocular Therapeutix™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that in...

Ocular Therapeutix™ Announces Executive Transition Plans

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that in...

Ocular Therapeutix™ To Present At Two Upcoming Investor Conferences

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar...

Keep Biotech Trigger Fingers Holstered

Keep Biotech Trigger Fingers Holstered

Three names show how fast biotechs can become oversold when the market acts in knee-jerk fashion.

Ocular Therapeutix™ Presented Phase 3 Data For DEXTENZA™ At The Association For Research In Vision And Ophthalmology (ARVO) Annual Meeting

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, presented ocular pain data...

Ocular Therapeutix™ Presents Preclinical Data On Pharmacokinetics, Efficacy And Tolerability Of Sustained Release Intravitreal Tyrosine Kinase Inhibitor Hydrogel Depot (OTX-TKI) At The ARVO Annual Meeting

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today presented data from...

Ocular Therapeutix™ Presents Additional Phase 3 Data And Patient Reported Outcomes Results For DEXTENZA™ At The American Society Of Cataract And Refractive Surgery (ASCRS) Symposium

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, presented yesterday new...

Ocular Therapeutix™ Reports First Quarter 2017 Financial Results

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced...

Ocular Therapeutix™ To Present Data On Anterior And Posterior Segment Drug Product Candidates At The Association For Research In Vision And Ophthalmology (ARVO) Annual Meeting

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that...

Ocular Therapeutix™ To Report First Quarter 2017 Financial Results

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that...

Commit To Purchase Ocular Therapeutix At $7.50, Earn 34% Annualized Using Options

Investors considering a purchase of Ocular Therapeutix Inc shares, but cautious about paying the going market price of $9.33/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $7.50 strike, which has a bid at the time of this writing of $1.00.

Ocular Therapeutix™ To Present Additional Phase 3 Data And Patient Reported Outcomes Results For DEXTENZA™ At The American Society Of Cataract And Refractive Surgery (ASCRS) Symposium

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced new...

Ocular Therapeutix™ Appoints George Migausky As Interim Chief Financial Officer

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced the...

New Publication Describes Positive Patient Experience In Study Of Ocular Therapeutix' DEXTENZA™ Following Cataract Surgery

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced positive...

Ocular Therapeutix™ Reports Fourth Quarter And Full Year 2016 Financial Results

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative drug products using its proprietary hydrogel platform technology for the...

Ocular Therapeutix™ To Report Fourth Quarter And Full Year 2016 Financial Results

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report...

TheStreet Quant Rating: D- (Sell)